Replies to post #117292 on NanoViricides Inc (NNVC)

[Rawnoc]

Nice try, but you "forgot" to include two things:

(1) "There are approximately 500,000 cases of ocular herpes per year in the United States. Fortunately, the vast majority can be effectively treated."

If the pie-in-the-sky miracle actually happens where NNVC actually accomplishes something with its flavor of the month, there is no way NNVC would it get $1,000 per treatment for a disease where the vast majority can already be effectively treated with cheaper other means.

(2) Your link from 2002 doesn't say "new" cases every year and doesn't list any sources. JG's link specifically says "new" cases and has a source. It also mentions the overall prevalence at 150 cases per 100,000 people which comes out quite close to 500,000.

[Rawnoc]

Thanks, but I prefer not to take bullshit:

Take some proportion of 500,000 people per year times $500-$2000 = many tens or hundreds of millions. I'm not sure what price the market would bear for an effective, rapid cure for ocular herpes, or what proportion of 500,000 people would seek treatment.

500,000 "people per year" is absolutely bullshit for which there is no link. 500,000 cases per year is the overall prevalence -- not new cases. A very tiny percentage of that figure is new cases.

Then according to your link it says the current methods are "effectively treated" so while it sounds great to say NNVC's nonexistent drug that has never even been manufactured to scale works better your link says "effective."

Long story short -- if NNVC actually accomplishes something with this latest flavor of the month, it will not make the company profitable.

2016 is a dead year heading for fresh lows.

Bank on it.